‘Pharma’ is less green: AstraZeneca, Novartis and Amgen leave the Dow Jones Sustainability Index

he Pharma Loses points in sustainability. New edition of Dow Jones Sustainability Index (Djsi) excluded three companies that were in the rankings a year ago, all from the pharmaceutical sector: AstraZeneca, Novartis, and Amgen.

The index, which highlights companies’ commitment to environmental, social and governance (ESG) aspects, included the three companies last year, but the three companies have now been excluded from the global rankings, despite AstraZeneca and Novartis entering the European rankings. classification.

“In 2023, there has been another strong response from companies, which see the value of disclosing their sustainability results to capital markets,” the company noted. In terms of market capitalization, the company removed the three pharmaceutical companies from the rankings, while adding Tencent Holdings, Philip Morris International and ServiceNow.

The Dow Jones Sustainability Index consists of those selected by Standard & Poor’s based on an assessment of the sustainability of global companies, through questionnaires designed to evaluate sustainability criteria that are financially relevant to economic, environmental and social dimensions. This time the index includes the top 10% of the 2,500 largest global companies in the S&P Global Broad Market Index.

In pharmaceuticals, Abbvie is at the forefront. the Biopharma American specialist in therapeutic areas such as immunology, oncology, neuroscience, eye care, virology and gastroenterology.

In the case of AbbVie, criteria such as the environmental dimension, contribution to health outcomes, good corporate governance and economic dimension, as well as risk and crisis management, among other aspects, are recognized.

Among the companies in the sector, Grifols, a Spanish company specializing in the production of plasma-derived medicines, was crowned the Spanish and European biopharmaceutical company with the highest score in the index.

Grifols has been listed on the DJSI for the fourth year in a rowThe company is distinguished by being a leader in the biotechnology sector, which this year (as of November 24, 2023) includes 372 companies according to the global Corporate Sustainability Assessment (CSA).

Another company in this sector in the lofty segment of the rating is Biogen. The American neuroscience company discovers, develops and provides innovative treatments for people with serious neurological and neurodegenerative diseases, as well as related adjacent therapies. Biogen, one of the world’s first biotechnology companies, was founded in 1978 By Charles Weismann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Philip Sharp.

Today, Biogen has a leading portfolio of drugs to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and has developed The first and only approved treatment that treats the specific pathology of Alzheimer’s disease.

Check Also

Alexandre Nascimento: From the textile industry to renewable energy

As our living standards intensify our hunger for energy, especially electricity, the current scenario reveals …

Leave a Reply

Your email address will not be published. Required fields are marked *